Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 11/20 | 0.40 |
| ▸ | PTGES | O14684 | 2/20 | 0.40 |
| ▸ | TOP2A | P11388 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.38 |
| ▸ | TYR | P14679 | 1/20 | 0.38 |
| ▸ | BID | P55957 | 2/20 | 0.38 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.38 |
| ▸ | BAK1 | Q16611 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5676838 | 0.99 | ALOX5 (0.39) | ALOX5PTGESTOP2APTPN1PPARG | |
| SCHEMBL5680719 | 0.96 | ALOX5 (0.44) | ALOX5PTGESTOP2APTPN1PPARG | |
| SCHEMBL5678078 | 0.96 | ALOX5 (0.40) | ALOX5PTGESTOP2APTPN1PPARG | |
| SCHEMBL5677895 | 0.94 | ALOX5 (0.43) | ALOX5PTGESTOP2APTPN1PPARG | |
| SCHEMBL5678562 | 0.94 | ALOX5 (0.43) | ALOX5PTGESTOP2APTPN1PPARG | |
| SCHEMBL5920566 | 0.94 | ALOX5 (0.43) | ALOX5PTGESTOP2APTPN1PPARG | |
| SCHEMBL5681114 | 0.94 | ALOX5 (0.40) | ALOX5PTGESTOP2APTPN1PPARG | |
| SCHEMBL5921127 | 0.94 | ALOX5 (0.43) | ALOX5PTGESTOP2APTPN1PPARG | |
| SCHEMBL5677030 | 0.93 | ALOX5 (0.42) | ALOX5PTGESTOP2APTPN1PPARG | |
| SCHEMBL5680727 | 0.92 | ALOX5 (0.41) | ALOX5PTGESTOP2APTPN1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060036049-A1 | Soluble late transition metal catalysts for olefin oligomerizations III | ZHAO BAIYI | 2006-02-16 | — | — | US | disclosed |
| EP-1620447-A1 | SOLUBLE LATE TRANSITION METAL CATALYSTS FOR OLEFIN OLIGOMERIZATIONS III | Exxonmobil Chemical Patents Inc. (US) | 2006-02-01 | — | — | EP | disclosed |
| WO-2003102006-A1 | SOLUBLE LATE TRANSITION METAL CATALYSTS FOR OLEFIN OLIGOMERIZATIONS III | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060036049-A1 | Soluble late transition metal catalysts for olefin oligomerizations III | COMT, CD69, SPR | ALOX5 833/4885PTGES 525/4885TOP2A 4237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.